Several reporters have been developed to estimate NMD activity in preclinical settings [92] and recent advances in whole cDNA sequencing could allow to quantify the whole activity of NMD and identify thousands of mRNAs targeted by NMD [24], exploitable as biomarkers to design a personalized approach and treat patients with NMD inhibitors for both genetic diseases and cancer. This evidence concerns the gene PLA1A and cancer.